Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?

Home P.

Diabetes Care. 2020 Feb;43(2):272-274. doi: 10.2337/dci19-0056. No abstract available.

PMID:
31959643
2.

Meal-time + basal insulin therapy: Is all not well?

Home P.

Diabetes Res Clin Pract. 2019 Nov;157:107923. doi: 10.1016/j.diabres.2019.107923. Epub 2019 Nov 9. No abstract available.

PMID:
31715202
3.

Regulation of human trophoblast syncytialization by histone demethylase LSD1.

Milano-Foster J, Ray S, Home P, Ganguly A, Bhattacharya B, Bajpai S, Pal A, Mason CW, Paul S.

J Biol Chem. 2019 Nov 15;294(46):17301-17313. doi: 10.1074/jbc.RA119.010518. Epub 2019 Oct 7.

PMID:
31591264
4.

Is Insulin Therapy Safe?

Home P, Itzhak B.

Am J Ther. 2020 Jan/Feb;27(1):e106-e114. doi: 10.1097/MJT.0000000000001077.

PMID:
31567197
5.

Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground.

Home P.

Diabetes Care. 2019 Sep;42(9):1615-1623. doi: 10.2337/dci19-0002. Epub 2019 Jun 8.

PMID:
31177180
6.

The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward.

Klonoff DC, Aron D, Cohen RM, Home P, John WG, Little RR, Nathan DM, Sacks DB.

J Diabetes Sci Technol. 2019 May;13(3):424-427. doi: 10.1177/1932296819841699. Epub 2019 Mar 22. No abstract available.

PMID:
30897963
7.

Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.

Shavadia JS, Sharma A, Gu X, Neaton J, DeLeve L, Holmes D, Home P, Eckel RH, Watkins PB, Granger CB.

Clin Trials. 2019 Jun;16(3):253-262. doi: 10.1177/1740774519836766. Epub 2019 Mar 18.

PMID:
30880443
8.

Cardiovascular outcome trials of glucose-lowering medications: an update.

Home P.

Diabetologia. 2019 Mar;62(3):357-369. doi: 10.1007/s00125-018-4801-1. Epub 2019 Jan 3. Review.

PMID:
30607467
9.

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.

Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB.

Diabetes Obes Metab. 2019 Feb;21(2):321-329. doi: 10.1111/dom.13607.

10.

Regulation of energy metabolism during early mammalian development: TEAD4 controls mitochondrial transcription.

Kumar RP, Ray S, Home P, Saha B, Bhattacharya B, Wilkins HM, Chavan H, Ganguly A, Milano-Foster J, Paul A, Krishnamurthy P, Swerdlow RH, Paul S.

Development. 2018 Oct 1;145(19). pii: dev162644. doi: 10.1242/dev.162644.

11.

2020 vision - An overview of prospects for diabetes management and prevention in the next decade.

Wang CY, Neil DL, Home P.

Diabetes Res Clin Pract. 2018 Sep;143:101-112. doi: 10.1016/j.diabres.2018.06.007. Epub 2018 Jun 23. Review.

12.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.

Home PD, Lam RLH, Carofano WL, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rosenstock J, Hollander PA, Gallwitz B.

Diabetes Obes Metab. 2018 Sep;20(9):2220-2228. doi: 10.1111/dom.13354. Epub 2018 Jun 5.

PMID:
29766635
13.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.

Hollander PA, Carofano WL, Lam RLH, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rendell MS, Home PD, Gallwitz B, Rosenstock J.

Diabetes Obes Metab. 2018 Sep;20(9):2229-2237. doi: 10.1111/dom.13363. Epub 2018 Jun 10.

PMID:
29761615
14.
15.

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.

Home P, Derwahl KM, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, Garg SK.

Diabetes Technol Ther. 2018 Feb;20(2):160-170. doi: 10.1089/dia.2017.0373.

16.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Riddle MC, Bolli GB, Avogaro A, Gimenez Álvarez M, Merino-Trigo A, Boëlle-Le Corfec E, Home PD.

Diabetes Metab. 2018 Sep;44(4):333-340. doi: 10.1016/j.diabet.2017.12.001. Epub 2017 Dec 11.

17.

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.

Home P, Calvi-Gries F, Blonde L, Pilorget V, Berlingieri J, Freemantle N.

Diabetes Obes Metab. 2018 Apr;20(4):921-929. doi: 10.1111/dom.13179. Epub 2018 Jan 7.

18.

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.

Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, Pong A, Suryawanshi S, Engel SS, Kaufman KD, Lai E.

Diabetes Res Clin Pract. 2018 Apr;138:253-261. doi: 10.1016/j.diabres.2017.10.018. Epub 2017 Oct 24.

19.

Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study.

Blonde L, Marre M, Vincent M, Brette S, Pilorget V, Danchin N, Vespasiani G, Home P.

Diabetes Res Clin Pract. 2017 Nov;133:150-158. doi: 10.1016/j.diabres.2017.08.016. Epub 2017 Aug 31.

20.

George Alberti: A Myriad of Contributions to Diabetes and Beyond.

Home P.

Diabetes Care. 2017 Sep;40(9):1154-1158. doi: 10.2337/dci17-0006. No abstract available.

PMID:
28830957
21.

Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.

Home PD, Ahrén B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, Miller D, Ambery P, Carr MC, Nauck MA.

Diabetes Res Clin Pract. 2017 Sep;131:49-60. doi: 10.1016/j.diabres.2017.06.013. Epub 2017 Jun 15.

PMID:
28683300
22.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC.

Diabetes Obes Metab. 2018 Jan;20(1):121-128. doi: 10.1111/dom.13048. Epub 2017 Aug 8.

23.

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD; EDITION 3 study investigators.

Diabetes Metab. 2017 Sep;43(4):351-358. doi: 10.1016/j.diabet.2017.04.007. Epub 2017 Jun 13.

24.

Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.

Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P.

Diabetes Technol Ther. 2017 Jul;19(7):391-399. doi: 10.1089/dia.2017.0054. Epub 2017 May 22. Review.

25.

GATA factors: Master regulators of gene expression in trophoblast progenitors.

Paul S, Home P, Bhattacharya B, Ray S.

Placenta. 2017 Dec;60 Suppl 1:S61-S66. doi: 10.1016/j.placenta.2017.05.005. Epub 2017 May 10. Review.

PMID:
28526138
26.

Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action.

Hirsch IB, Martinez J, Dorsey ER, Finken G, Fleming A, Gropp C, Home P, Kaufer DI, Papapetropoulos S.

Clin Ther. 2017 May;39(5):1064-1076. doi: 10.1016/j.clinthera.2017.03.018. Epub 2017 Apr 14.

27.

Genetic redundancy of GATA factors in the extraembryonic trophoblast lineage ensures the progression of preimplantation and postimplantation mammalian development.

Home P, Kumar RP, Ganguly A, Saha B, Milano-Foster J, Bhattacharya B, Ray S, Gunewardena S, Paul A, Camper SA, Fields PE, Paul S.

Development. 2017 Mar 1;144(5):876-888. doi: 10.1242/dev.145318.

28.

Diabetes: A diabetes mellitus guideline gone wrong - the 2017 ACP update.

Home P.

Nat Rev Endocrinol. 2017 Apr;13(4):191-192. doi: 10.1038/nrendo.2017.9. Epub 2017 Feb 3. No abstract available.

PMID:
28155903
31.

Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?

Giorgino F, Home PD, Tuomilehto J.

Diabetes Care. 2016 Aug;39 Suppl 2:S187-95. doi: 10.2337/dcS15-3023.

PMID:
27440832
32.

Clinical use of the co-formulation of insulin degludec and insulin aspart.

Kumar A, Awata T, Bain SC, Ceriello A, Fulcher GR, Unnikrishnan AG, Arechavaleta R, Gonzalez-Gálvez G, Hirose T, Home PD, Kaku K, Litwak L, Madsbad S, Pinget M, Mehta R, Mithal A, Tambascia M, Tibaldi J, Christiansen JS.

Int J Clin Pract. 2016 Aug;70(8):657-67. doi: 10.1111/ijcp.12821. Epub 2016 Jul 7. Review.

PMID:
27384031
33.

IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status.

Christiansen JS, Home P, Kumar A.

Expert Rev Endocrinol Metab. 2016 Mar;11(2):103-111. doi: 10.1586/17446651.2016.1145541.

PMID:
30058868
34.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.

Riddle MC, Bolli GB, Home PD, Bergenstal RM, Ziemen M, Muehlen-Bartmer I, Wardecki M, Vinet L, Jeandidier N, Yki-Järvinen H.

Diabetes Technol Ther. 2016 Apr;18(4):252-7. doi: 10.1089/dia.2015.0290. Epub 2016 Feb 3.

35.

Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?

Home P.

Diabetes Care. 2015 Dec;38(12):2234-6. doi: 10.2337/dc15-1046. No abstract available.

PMID:
26604277
36.

Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.

Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD.

Diabetes Obes Metab. 2016 Feb;18(2):152-8. doi: 10.1111/dom.12598. Epub 2015 Dec 23.

37.

Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, Hu FB, Raz I, Van Gaal L, Wolfe BM, Ryan DH.

Diabetes Care. 2015 Aug;38(8):1567-82. Review.

38.

Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research.

Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P.

Diabetes Care. 2015 Sep;38(9):1627-33. doi: 10.2337/dc14-2919. No abstract available.

PMID:
26294772
39.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC.

Diabetes Care. 2015 Dec;38(12):2217-25. doi: 10.2337/dc15-0249. Epub 2015 Jun 17.

PMID:
26084341
40.

Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

Home PD.

Diabetes Obes Metab. 2015 Nov;17(11):1011-20. doi: 10.1111/dom.12501. Epub 2015 Sep 23. Review.

41.

Biosimilar insulins: guidance for data interpretation by clinicians and users.

Heinemann L, Home PD, Hompesch M.

Diabetes Obes Metab. 2015 Oct;17(10):911-8. doi: 10.1111/dom.12491. Epub 2015 Jul 1. Review.

42.
43.

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.

Home PD, Dain MP, Freemantle N, Kawamori R, Pfohl M, Brette S, Pilorget V, Scherbaum WA, Vespasiani G, Vincent M, Balkau B.

Diabetes Res Clin Pract. 2015 May;108(2):350-9. doi: 10.1016/j.diabres.2015.01.030. Epub 2015 Jan 23.

44.

Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study.

Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD.

Diabetes Res Clin Pract. 2015 Jun;108(3):432-40. doi: 10.1016/j.diabres.2015.02.034. Epub 2015 Mar 12.

45.

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins.

Heinemann L, Khatami H, McKinnon R, Home P.

Diabetes Technol Ther. 2015 Jul;17(7):510-26. doi: 10.1089/dia.2014.0362. Epub 2015 Mar 19. Review.

46.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators.

Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.

47.

Cancer and bone fractures in observational follow-up of the RECORD study.

Jones NP, Curtis PS, Home PD.

Acta Diabetol. 2015 Jun;52(3):539-46. doi: 10.1007/s00592-014-0691-y. Epub 2014 Dec 19.

PMID:
25524432
48.

A common fallacy of observational medication studies in diabetes.

Home PD.

Diabetes Obes Metab. 2015 Apr;17(4):317-8. doi: 10.1111/dom.12421. Epub 2014 Dec 23. No abstract available.

PMID:
25440575
49.

Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation.

Brooks AM, Oram R, Home P, Steen N, Shaw JA.

Diabetes Care. 2015 Jan;38(1):105-12. doi: 10.2337/dc14-1656. Epub 2014 Nov 24.

PMID:
25422169
50.

Response to comment on Balkau et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014;37:2108-2113.

Balkau B, Home PD, Vincent M, Marre M, Freemantle N.

Diabetes Care. 2014 Dec;37(12):e266. doi: 10.2337/dc14-2152. No abstract available.

PMID:
25414401

Supplemental Content

Support Center